GLP1R and kidney disorder: Importantly, payer reimbursement restrictions are probably in place because previous cost-effectiveness analyses of these medications have considered at least some measure of their glycaemic benefits [13, 14], while whether SGLT2is and GLP-1 RAs are cost-effective solely on the basis of their benefits on cardiovascular and kidney disease has never been studied as far as we are aware.